Volume 26, Issue 4 - Preclinical Studies
Reporting of preclinical research: What do we get told – when and how?
Abstract
At present, there are no specific requirements for the reporting of preclinical research, and many studies, particularly those with negative results, never get published. Despite the huge advances in communication opportunities, things have not really changed throughout the history of drug development. Sometimes researchers and scientists are hesitant to release results prematurely and there is a culture not to publish when studies have negative findings. However, routine and reliable reporting of all research – preclinical, clinical, laboratory, animal or human based, and with positive or negative outcomes – is essential to the future of collaborative and successful clinical research. There are several new ideas to promote this, and hopefully in years to come we will see all research results easily accessible and widely used.
Download the full article
References
-
California Biomedical Research Association. Fact Sheet of the New Drug Development Process, California Biomedical Research Association. [cited 2017 Sep 10].
Available from: https://www.ca-biomed.org/pdf/mediakit/ fact-sheets/CBRADrugDevelop.pdf
-
AllTrials. All Trials (Homepage). 2016 [cited 2017 Sep 10].
Available from: http://www.alltrials.net/
-
Matosin N, Frank E, Engel M, Lum JS, Newell KA. Negativity towards negative results: A discussion of the disconnect between scientific worth and scientific culture. Dis Model Mech. 2014;7(2):171–3.
Available from: http://
-
Scott D. Califf’s big idea: Build a database for research done before clinical trials. Stat News. 2016 June 10 [cited 2017 Sep 10].
Available from: https://www.statnews. com/2016/06/10/califf-databasepreclinical-trials/
-
U.S. National Library of Medicine. ClinicalTrials.gov (Homepage). 2016 [cited 2017 Sep 10].
Available from: https://clinicaltrials.gov
-
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altram DG. Animal research: Reporting of in vivo experiments, National Centre for the Replacement, Refinement and Reduction of Animals in Research. Originally published in PLOS biology, 2010 Jun 29. [cited 2017 Sep 10]
Available from: https://www.nc3rs.org.uk/arriveguidelines
-
Equator Network. Enhancing the Quality of Healthcare Research (Homepage). 2017 [cited 2017 Sep 10].
Available from: http://www.equator-network.org/ reporting-guidelines/
-
U.S. Food and Drug Administration. CFR - Code of Federal Regulations, Title 21. 2017. [cited 2017 Sep 10].
Available from: https://www.accessdata.fda.gov/scripts/cd rh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart =58
-
BioMed Central. Translational Medicine Communications (Homepage). 2016 [cited 2017 Sep 10].
Available from: https:// transmedcomms.biomedcentral. com/
-
Moore A. Eternal sunshine. The Guardian. 2007 [cited 2017 Sep 10].
Available from: https://www.theguardian.com/society/20 07/may/13/socialcare.medicineandhealth
-
Hong LZ, Huang KF, Hung SW, Kuo LT. Chronic fluoxetine treatment enhances sympathetic activities associated with abnormality of baroreflex function in conscious normal rats. Eur J Pharmacol. 2017;811:164–70. doi: 10.1016/j.ejphar. 2017.06.021. Epub 2017 Jun 16.
Available from: http://
-
Connelly D. A history of aspirin. Clinic Pharm. 2014;6(7).
Available from: http://
-
Sneader W. The discovery of aspirin: A reappraisal. Brit Med J. 2000;321:1591–4.
Available from: http://
-
Dunbar C. Belfast scientists say aspirin could reverse tooth decay. BBC News NI (Blogsite). 2017 [cited 2017 Sep 10].
Available from: http://www.bbc.co.uk/ news/uk-northern-ireland-41180006
-
Committee on Strategies for Responsible Sharing of Clinical Trial Data, Board on Health Sciences Policy, Institute of Medicine. Sharing clinical trial data: Maximizing benefits, minimizing risk – 4. The clinical trial life cycle and when to share data. Washington (DC): National Academies Press (US); 2015 . [cited 2017 Sep 10].
Available from: https://www.ncbi. nlm.nih.gov/books/NBK286004